.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

EXELON Drug Profile

« Back to Dashboard
Exelon is a drug marketed by Novartis and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in EXELON is rivastigmine. There are thirty-two drug master file entries for this compound. Four suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the rivastigmine profile page.

Summary for Tradename: EXELON

Patents:2
Applicants:1
NDAs:3
Suppliers / Packagers: see list3
Drug Prices: :see details

Pharmacology for Tradename: EXELON

Clinical Trials for: EXELON

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 2000RXYes
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083-001Jul 6, 2007RXNo6,316,023Jan 8, 2019Y
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 2000RXYes
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: EXELON

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-004Apr 21, 20004,948,807<disabled>
Novartis
EXELON
rivastigmine tartrate
SOLUTION;ORAL021025-001Apr 21, 20005,602,176<disabled>
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-004Apr 21, 20005,602,176<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EXELON

Drugname Dosage Strength RLD Submissiondate
rivastigmineTransdermal System Extended-release13.3 mg/24 hrExelon1/22/2013
rivastigmineTransdermal System Extended-release4.6 mg/24 hr and 9.5 mg/24 hrExelon Patch4/27/2011
rivastigmine tartrateOral Solution2 mg/mLExelon11/5/2004
rivastigmine tartrateCapsules1.5 mg, 3 mg, 4.5 mg and 6 mgExelon4/21/2004

International Patent Family for Tradename: EXELON

Country Document Number Estimated Expiration
Poland341347<disabled in preview>
World Intellectual Property Organization (WIPO)9934782<disabled in preview>
Hungary227159<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: EXELON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/041United Kingdom<disabled>PRODUCT NAME: RIVASTIGMINE, AS FREE BASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5427501 19970731; CH 5427502 19970731; CH 5427503 19970731; CH 5427504 19970731; CH 5427505 19970731; CH 5427506 19970731; UK EU/1/98/066/001 19980512; UK EU/1/98/066/002 19980512; UK EU/1/98/066/003 19980512; UK EU/1/98/066/004 19980512; UK EU/1/98/066/005 19980512; UK EU/1/98/066/006 19980512; UK EU/1/98/092/023 19980512; UK EU/1/98/092/024 19980512; UK EU/1/98/092/025 19980512; UK EU/1/98/092/026 19980512; UK EU/1/98/066/025 19980512; UK EU/1/98/066/026 19980512; UK EU/1/98/092/019 19980512; UK EU/1/98/092/020 19980512; UK EU/1/98/092/021 19980512; UK EU/1/98/092/022 19980512; UK EU/1/98/0
C0038Belgium<disabled>PRODUCT NAME: RIVASTIGMINE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512; FIRST REGISTRATION: CH 54275 01 19970731
80031Netherlands<disabled>PRODUCT NAME: RIVASTIGMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER RIVASTIGMINE WATERSTOFTAR- TRAAT; REGISTRATION NO/DATE: EU/1/98/066/001 - EU/1/98/066/012 19980512
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc